|January 2008 · Vol. 20, No. 01
Aromatase inhibitors, a new option for inducing ovulation
This class of drugs may boost the pregnancy rate in selected populations
Aromatase inhibitors suppress estrogen production in the ovaries, brain, and adipose tissue
Aromatase inhibitors do not appear to affect expression of estrogen receptors in the endometrium and cervix
Success with an aromatase inhibitor is unlikely when there is no appropriate indication for clomiphene citrate
Because the aromatase enzyme is expressed in endometriotic lesions, aromatase inhibitors may have the added benefit of suppressing endometriosis
In a recent study, letrozole was associated with a significantly lower rate of multiple gestation than was clomiphene citrate
A large study found a similar incidence of cardiac anomaly among women treated with letrozole and the general population
Dr. Mitwally is Reproductive Endocrinologist and Infertility Specialist, Reproductive Medicine and Fertility Center, Colorado Springs, Colo. He is also Clinical Assistant Professor, Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, at the University of New Mexico in Albuquerque.Robert
Dr. Casper is Professor in the Reproductive Sciences Division, Department of Obstetrics and Gynecology, at the University of Toronto in Toronto, Ontario.
Dr. Mitwally holds patents licensed to Serono for use of aromatase inhibitors for infertility treatment.
Dr. Casper has a licensing agreement with Ares-Serono for use of aromatase inhibitors in assisted reproduction.